Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zurletrectinib (ICP-723) in Advanced Solid Tumors and Primary CNS Tumors
NCT05745623Phase 2Recruiting
- Sponsor
- InnoCare Pharma
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zurlectrectinib in solid tumor and primary central nervous system tumors, sponsored by InnoCare Pharma. Primary endpoint: Objective Response Rate. Started Dec 2022; status: recruiting.
02
Drugs
zurlectrectinib
03
Conditions
solid tumorprimary central nervous system tumors
Beyond the preview
Go deeper on NCT05745623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745623.